All sponsors

Xynomic Pharmaceuticals, Inc.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-31
RECRUITING2
READOUTS ≤12 MONTHS1
READOUT SLIPPED >6 MO100%

Delay Index: of 5 active trials registered more than a year ago, 5 have moved their primary completion (readout) date by more than 6 months since first registration (median +50.5 months). See all sponsors →

Open Xynomic Pharmaceuticals, Inc. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Abexinostat
NCT04024696
P1/2Active, not recruitingNon Hodgkin Lymphoma122024-12-30 (+50 mo)
Abexinostat
NCT03934567
P2Active, not recruitingLymphoma, Follicular872025-01-29
abexinostat
NCT03936153
P2RecruitingDiffuse Large B-cell Lymphoma (DLBCL)1702026-07-31 (+40 mo)
Pazopanib
NCT03592472
P3RecruitingRenal Cell Carcinoma4132026-12-30 (+59 mo)
ENHANCE
NCT05275374
P1/2Not yet recruitingCancer; BRAF V600 Mutation2212027-12-30 (+37 mo)
FORERUNNER
NCT03600441
P2Active, not recruitingFollicular Lymphoma1392027-12-31 (+108 mo)